ADC Therapeutics — Q4 2026 Earnings Summary

Financial Performance:

• The press release does not disclose specific financial figures such as revenue, earnings, profit margins, cash flow, deferred revenue, or debt levels.
• The document mentions "expected revenue growth in 2027" and "expected cash runway into 2029" as forward-looking statements but provides no quantitative data.
• Indebtedness to HealthCare Royalty Management, Blue Owl, and Oaktree is noted, along with the significant cash required to service such debt, but no specific debt amounts are listed.

Guidance and Future Outlook:

• Management anticipates expected revenue growth in 2027 and the ability to sustain or grow ZYNLONTA revenue in the future.
• The company expects a cash runway extending into 2029.
• Future plans include pursuing potential compendia and regulatory pathways to expand ZYNLONTA's role in treating B-cell malignancies.
• Planned Phase 3 studies are mentioned for the combination of ZYNLONTA plus glofitamab.
• The company is evaluating the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions, including earlier lines of therapy.
• The company is assessing the potential for NCCN compendia inclusion for LOTIS-7 trial data and investigator-initiated trials.
• A potential change in domicile from Switzerland to Delaware is under evaluation, subject to shareholder approval and tax analysis.

Business Segments and Product Lines:

• ZYNLONTA (loncastuximab tesirine-lpyl): The company's sole commercial product, a CD19-directed antibody drug conjugate (ADC).
• LOTIS-7 (Phase 1b): Evaluated ZYNLONTA plus glofitamab in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Among 97 efficacy-evaluable patients, the overall response rate (ORR) was 88.7% and complete response rate (CRR) was 75.3%. In patients with primary refractory disease, ORR was 78.4% and CRR was 64.7%. Among patients previously treated with CAR-T therapy, ORR was 74.1% and CRR was 63.0%. At a median follow-up of 10.35 months, median duration of response, duration of complete response, and progression-free survival (PFS) had not been reached; the 12-month duration of complete response rate was 79.0%.
• Marginal Zone Lymphoma (Phase 2 IIT): Evaluated fixed-duration ZYNLONTA monotherapy in r/r marginal zone lymphoma (MZL). Among 43 efficacy-evaluable patients, ORR was 93% and CRR was 74.4%. At a median follow-up of 23.2 months, the two-year PFS rate was 90.8%, and the duration of response rate at 24 months was 90.9%.
• LOTIS-5 (Phase 3): Evaluated ZYNLONTA plus rituximab versus R-GemOx in r/r DLBCL. Among 420 patients, median PFS was 6.14 months with ZYNLONTA plus rituximab versus 4.73 months with R-GemOx (HR 0.73; P=0.0083). ORR was 58.1% versus 45.2%, and CRR was 39.5% versus 26.7%. Median duration of complete response was 16.82 months versus 12.25 months. At 24 months, 48.5% of patients in the ZYNLONTA arm remained in complete response versus 16.7% in the control arm. No statistically significant difference in overall survival was observed.
• Other Trials: Data presented from investigator-initiated trials in r/r mantle cell lymphoma (MCL) and r/r Waldenström macroglobulinemia (WM).
• Japan Partnership: Tanabe's marketing authorization application for ZYNLONTA has been filed with Japan's Ministry of Health; the timing and potential approval are under review.

Market and Competitive Landscape:

• ZYNLONTA is approved by the FDA under accelerated approval and by the European Commission under conditional approval for r/r DLBCL after two or more lines of systemic therapy.
• The company positions ZYNLONTA as a "best-in-class" potential treatment and a standard treatment option in the second-line or later setting based on LOTIS-5 results.
• Responses in the MZL study were characterized as comparable to those reported for recently approved CAR-T therapy.
• The company is a commercial-stage global leader in antibody drug conjugates (ADCs).

Risks and Challenges:

• Regulatory Approval: Risks include the adequacy of LOTIS-5 data to support full regulatory approval, the ability to maintain accelerated approval in the U.S. and foreign jurisdictions, and the outcome of meetings with the FDA regarding serious concerns raised during the pre-sBLA submission.
• Safety Profile: The LOTIS-5 trial showed Grade 5 treatment-emergent adverse events in 13.2% of patients in the ZYNLONTA arm versus 4.6% in the R-GemOx arm within the 105-day window.
• Debt Obligations: The company faces restrictions on activities due to indebtedness to HealthCare Royalty Management, Blue Owl, and Oaktree, and the significant cash required to service this debt.
• Commercialization: Risks include the ability of partners to commercialize ZYNLONTA in foreign markets and the timing/amount of future revenue and payments from these partnerships.
• Redomiciliation: Uncertainties exist regarding a potential change of domicile from Switzerland to Delaware, including tax analysis outcomes and shareholder approval.
• Trade Policies: International trade policies, including tariffs, sanctions, and drug pricing regulations, may impact the business.

Management Commentary and Tone:

• Mohamed Zaki, MD, PhD (Chief Medical Officer), expressed pleasure with the breadth of the ZYNLONTA clinical program and encouragement regarding the strength of updated LOTIS-7 and MZL data, noting deep and durable efficacy with manageable safety.
• Ameet Mallik (Chief Executive Officer) stated that emerging data reinforce the best-in-class potential of ZYNLONTA and support the pursuit of an expanded role in treating B-cell malignancies. He emphasized the company's focus on delivering meaningful patient outcomes while driving long-term shareholder value.

Other Key Points:

• ASH Meeting: ADC Therapeutics will present five oral abstracts and multiple posters at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12–15, 2026.
• Conference Call: A conference call was hosted on November 4, 2026, at 4:15 p.m. EST to discuss the data.
• Safety Data (LOTIS-7): Cytokine release syndrome (CRS) occurred in 32% of treated patients (predominantly Grade 1 or 2). One Grade 3 CRS event was reported, and no Grade 3 or higher ICANS events occurred. Three Grade 5 treatment-emergent adverse events were reported.
• Safety Data (LOTIS-5): Within the 105-day window, Grade 3 or higher events occurred in 74.0% of the ZYNLONTA arm versus 76.1% of the R-GemOx arm. Grade 5 events occurred in 13.2% versus 4.6%, respectively.
• Safety Data (MZL IIT): Grade 3 AEs were reported in 50% of patients, and Grade 4 AEs in 10.9%. Four patients required dose reductions.
• MRD Analysis: In LOTIS-7, 50% of patients who achieved a complete response had undetectable minimal residual disease (MRD) by Cycle 2, Day 1.
• Manufacturing: The company maintains specialized capabilities from clinical to manufacturing and commercialization, with operations in Lausanne, Switzerland, and New Jersey.